Koers Atossa Genetics Inc Nasdaq
Aandelen
US04962H1005
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 208 mln. 193 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -35 mln. -32,5 mln. | Nettowinst (verlies) 2025 * | -39 mln. -36,22 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-6,09
x | K/w-verhouding 2025 * |
-5,72
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,9% |
Recentste transcriptie over Atossa Genetics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 01-12-08 |
Steven Quay
CEO | Chief Executive Officer | 73 | 01-12-08 |
Heather Rees
DFI | Director of Finance/CFO | - | 01-01-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 01-12-08 |
Director/Board Member | 66 | 01-03-14 | |
H. Remmel
BRD | Director/Board Member | 72 | 01-02-12 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+22,81% | 47,9 mld. | |
+46,56% | 41,42 mld. | |
-1,88% | 40,7 mld. | |
-6,20% | 28,92 mld. | |
+11,33% | 25,55 mld. | |
-21,00% | 19,27 mld. | |
-1,43% | 12,15 mld. | |
+30,73% | 12,14 mld. | |
-0,48% | 11,99 mld. |
- Beurs
- Aandelen
- Koers ATOS
- Koers